Get started
Author

Pavlina Jimbei

Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study
2019 · Gilbert Habib, Paola Anna Erba, et al. · European Heart Journal · 947
PDF
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
2017 · Michel Bazinet, Victor Pântea, et al. · The Lancet. Gastroenterology & hepatology · 263
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
2020 · Michel Bazinet, Victor Pântea, et al. · Gastroenterology · 255
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
2020 · Michel Bazinet, Victor Pântea, et al. · Hepatology Communications · 93
The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry
2019 · Gilbert Habib, Patrizio Lancellotti, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 87
PDF
Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry
2022 · William K F Kong, Antonio Salsano, et al. · European Heart Journal · 82
PDF
Infective endocarditis in adult patients with congenital heart disease
2022 · Joost P. van Melle, Jolien W. Roos-Hesselink, et al. · International Journal of Cardiology · 53
Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry
2023 · Antonia Sambola, Jordi Lozano-Torres, et al. · European Heart Journal · 52
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
2020 · Louis Shekhtman, Scott J. Cotler, et al. · Scientific Reports · 44
PDF
Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry
2022 · Michal Pazdernik, Bernard Iung, et al. · Infection · 37
Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study
2018 · M. Bazinet, V. Pantea, et al. · Journal of Hepatology · 26
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy
2021 · Michel Bazinet, Mark Anderson, et al. · Hepatology Communications · 22
Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection
2017 · M. Bazinet, V. Pantea, et al. · Journal of Hepatology · 21
HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection
2022 · Michel Bazinet, Mark Anderson, et al. · Hepatology Communications · 20
LO2 : Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection
2015 · M. Bazinet, V. Pantea, et al. · Journal of Hepatology · 18
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy
2021 · Michel Bazinet, Victor Pântea, et al. · Journal of Viral Hepatitis · 17
Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a
2018 · A. Vaillant, M. Bazinet, et al. · Journal of Hepatology · 15
Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection
2016 · M. Bazinet, V. Pantea, et al. · Journal of Hepatology · 14
FRI-210-Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study
2019 · Michel Bazinet, Victor Pantea, et al. · Journal of Hepatology · 9
One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
2017 · M. Bazinet, V. Pantea, et al. · Journal of Hepatology · 6
Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies
2020 · Michel Bazinet, Mark Anderson, et al. · Journal of Hepatology · 5
PDF
Clinical characteristics, management and outcomes of enterococcal infective endocarditis: an ancillary study from the ESC-EORP EURO-ENDO registry
2025 · Mary Philip, Robinson Gravier Dumonceau, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 4
FRI-211-Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection
2019 · Michel Bazinet, Victor Pantea, et al. · Journal of Hepatology · 1
Correction to: Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry
2022 · Michal Pazdernik, Bernard Iung, et al. · Infection
PDF
FRI-168-Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling
2019 · Louis Shekhtman, Scott Cotler, et al. · Journal of Hepatology
Works count: 25
Citation count: 2,091
H-index: 16
I10-index: 18
Year
Topic
Type